SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973753485> ?p ?o ?g. }

Showing items 1 to 100 of ±128 with 100 items per page.

W1973753485 endingPage "311" @default.
W1973753485 startingPage "301" @default.
W1973753485 abstract "Background GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients achieving an overall objective response, compared with chemotherapy alone. In this study, we aimed to analyse patient-reported outcomes in GOG 240. Methods Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease and GOG performance status of 0–1. Participants were randomly assigned by web-based permuted block randomisation (block size 4) in a 1:1:1:1 ratio to the four treatment groups: cisplatin (50 mg/m2 intravenously on day 1 or 2 of the treatment cycle) and paclitaxel (135 mg/m2 intravenously over 24 h or 175 mg/m2 intravenously over 3 h on day 1), with or without bevacizumab (15 mg/kg intravenously on day 1 or 2), or paclitaxel (175 mg/m2 over 3 h on day 1) and topotecan (0·75 mg/m2 for 30 min on days 1–3) with or without bevacizumab (15 mg/kg intravenously on day 1). Treatment assignment was concealed at randomisation (everyone was masked to treatment assignment, achieved by the use of a computer encrypted numbering system at the National Cancer Institute) and became open-label when each patient was registered to the trial. Treatment cycles were repeated every 21 days until disease progression or unacceptable toxicity, whichever occurred first. The coprimary endpoints of the trial were overall survival and safety; the primary quality-of-life endpoint was the score on the Functional Assessment of Cancer Therapy-Cervix Trial Outcome Index (FACT-Cx TOI). For our analysis of patient-reported outcomes, participants were assessed before treatment cycles 1, 2, and 5, and at 6 and 9 months after the start of cycle 1, with the FACT-Cx TOI, items from the FACT-GOG-Neurotoxicity subscale, and a worst pain item from the Brief Pain Inventory. All patients who completed baseline quality-of-life assessments and at least one further follow-up assessment were evaluable for quality-of-life outcomes. This study is registered with ClinicalTrials.gov, number NCT00803062. Findings Between April 6, 2009, and Jan 3, 2012, a total of 452 patients were enrolled in the trial, of whom 390 completed baseline quality-of-life assessment and at least one further assessment and were therefore evaluable for quality-of-life outcomes. In these patients, patient-reported outcome completion declined from 426 (94%) of 452 (at baseline) to 193 (63%) of 307 (9 months post-cycle 1), but completion rates did not differ significantly between treatment regimens (p=0·78). The baseline FACT-Cx TOI scores did not differ significantly between patients who received bevacizumab versus those who did not (p=0·27). Compared with patients who received chemotherapy alone, patients who received chemotherapy plus bevacizumab reported FACT-Cx TOI scores that were an average of 1·2 points lower (98·75% CI −4·1 to 1·7; p=0·30). Interpretation Improvements in overall survival and progression-free survival attributed to the incorporation of bevacizumab into the treatment of advanced cervical cancer were not accompanied by any significant deterioration in health-related quality of life. Patients responding to anti-angiogenesis therapy who maintain an acceptable quality of life could be suitable at progression for treatment with other novel therapies that might confer additional benefit. Funding National Institutes of Health." @default.
W1973753485 created "2016-06-24" @default.
W1973753485 creator A5009967316 @default.
W1973753485 creator A5014432118 @default.
W1973753485 creator A5014611244 @default.
W1973753485 creator A5019439628 @default.
W1973753485 creator A5022267430 @default.
W1973753485 creator A5028360591 @default.
W1973753485 creator A5029359855 @default.
W1973753485 creator A5035607232 @default.
W1973753485 creator A5046956876 @default.
W1973753485 creator A5055050872 @default.
W1973753485 creator A5073591360 @default.
W1973753485 creator A5086996122 @default.
W1973753485 creator A5089955620 @default.
W1973753485 creator A5091136643 @default.
W1973753485 date "2015-03-01" @default.
W1973753485 modified "2023-09-30" @default.
W1973753485 title "Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240)" @default.
W1973753485 cites W1868204754 @default.
W1973753485 cites W1979608435 @default.
W1973753485 cites W1981747359 @default.
W1973753485 cites W1985609148 @default.
W1973753485 cites W1987940634 @default.
W1973753485 cites W2002330540 @default.
W1973753485 cites W2004732318 @default.
W1973753485 cites W2012068442 @default.
W1973753485 cites W2014779151 @default.
W1973753485 cites W2030859744 @default.
W1973753485 cites W2040935111 @default.
W1973753485 cites W2045849258 @default.
W1973753485 cites W2073942227 @default.
W1973753485 cites W2078032294 @default.
W1973753485 cites W2080861151 @default.
W1973753485 cites W2090031841 @default.
W1973753485 cites W2100756525 @default.
W1973753485 cites W2105258029 @default.
W1973753485 cites W2118508302 @default.
W1973753485 cites W2118709016 @default.
W1973753485 cites W2120680348 @default.
W1973753485 cites W2126768246 @default.
W1973753485 cites W2131156214 @default.
W1973753485 cites W2144429930 @default.
W1973753485 cites W2171725862 @default.
W1973753485 doi "https://doi.org/10.1016/s1470-2045(15)70004-5" @default.
W1973753485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4479218" @default.
W1973753485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25638326" @default.
W1973753485 hasPublicationYear "2015" @default.
W1973753485 type Work @default.
W1973753485 sameAs 1973753485 @default.
W1973753485 citedByCount "115" @default.
W1973753485 countsByYear W19737534852015 @default.
W1973753485 countsByYear W19737534852016 @default.
W1973753485 countsByYear W19737534852017 @default.
W1973753485 countsByYear W19737534852018 @default.
W1973753485 countsByYear W19737534852019 @default.
W1973753485 countsByYear W19737534852020 @default.
W1973753485 countsByYear W19737534852021 @default.
W1973753485 countsByYear W19737534852022 @default.
W1973753485 countsByYear W19737534852023 @default.
W1973753485 crossrefType "journal-article" @default.
W1973753485 hasAuthorship W1973753485A5009967316 @default.
W1973753485 hasAuthorship W1973753485A5014432118 @default.
W1973753485 hasAuthorship W1973753485A5014611244 @default.
W1973753485 hasAuthorship W1973753485A5019439628 @default.
W1973753485 hasAuthorship W1973753485A5022267430 @default.
W1973753485 hasAuthorship W1973753485A5028360591 @default.
W1973753485 hasAuthorship W1973753485A5029359855 @default.
W1973753485 hasAuthorship W1973753485A5035607232 @default.
W1973753485 hasAuthorship W1973753485A5046956876 @default.
W1973753485 hasAuthorship W1973753485A5055050872 @default.
W1973753485 hasAuthorship W1973753485A5073591360 @default.
W1973753485 hasAuthorship W1973753485A5086996122 @default.
W1973753485 hasAuthorship W1973753485A5089955620 @default.
W1973753485 hasAuthorship W1973753485A5091136643 @default.
W1973753485 hasBestOaLocation W19737534852 @default.
W1973753485 hasConcept C121608353 @default.
W1973753485 hasConcept C126322002 @default.
W1973753485 hasConcept C141071460 @default.
W1973753485 hasConcept C143998085 @default.
W1973753485 hasConcept C168563851 @default.
W1973753485 hasConcept C203092338 @default.
W1973753485 hasConcept C2776694085 @default.
W1973753485 hasConcept C2777802072 @default.
W1973753485 hasConcept C2778220009 @default.
W1973753485 hasConcept C2780435969 @default.
W1973753485 hasConcept C2781209748 @default.
W1973753485 hasConcept C535046627 @default.
W1973753485 hasConcept C71924100 @default.
W1973753485 hasConceptScore W1973753485C121608353 @default.
W1973753485 hasConceptScore W1973753485C126322002 @default.
W1973753485 hasConceptScore W1973753485C141071460 @default.
W1973753485 hasConceptScore W1973753485C143998085 @default.
W1973753485 hasConceptScore W1973753485C168563851 @default.
W1973753485 hasConceptScore W1973753485C203092338 @default.
W1973753485 hasConceptScore W1973753485C2776694085 @default.
W1973753485 hasConceptScore W1973753485C2777802072 @default.
W1973753485 hasConceptScore W1973753485C2778220009 @default.